NCT01448239 - Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Hypercholesterolemia

Interventions

DRUG

alirocumab SAR236553 (REGN727)

Pharmaceutical form:Solution Route of administration: Subcutaneous

DRUG

alirocumab SAR236553 (REGN727)

Pharmaceutical form:Solution Route of administration: Subcutaneous

Trial Locations (1)

Sanofi-Aventis Administrative Office, Bridgewater